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(VAs) in arrhythmogenic right ventricular cardiomyopathy (ARVC)
are correlated with physical exercise, and clinical detraining and
avoidance of competitive sport practice are suggested for ARVC
patients. An algorithm assessing primary arrhythmic risk in ARVC
patients was recently developed by Cadrin-Tourigny et al. Data
regarding its transferability to athletes are lacking.
OBJECTIVE The purpose of this study was to assess the reliability of
the Cadrin-Tourigny risk prediction algorithm in a cohort of athletes
with ARVC and to describe the impact of clinical detraining on dis-
ease progression.
METHODS All athletes undergoing clinical detraining after ARVC
diagnosis at our institution were enrolled. Baseline and follow-up
clinical characteristics and data on VA events occurring during
follow-up were collected. The Cadrin-Tourigny algorithm was used
to calculate the a priori predicted VA risk, which was compared
with the observed outcomes.
RESULTS Twenty-five athletes (age 36.1 6 14.0 years; 80% male)
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(3.2–6.6) years, a reduction in premature ventricular complex
(PVC) burden (P 5 .001) was assessed, and 10 VA events (40%)
were recorded. The a priori algorithm-predicted risk seemed to fit
with the observed cohort arrhythmic risk [mean observed–
predicted risk difference over 5 years –0.85% (interquartile range
–4.8% to 13.1%); P 5 .85]. At 1-year follow-up, 11 patients
(44%) had an improved stress ECG response, and no significant
changes in right ventricular ejection fraction were observed.
CONCLUSION Clinical detraining is associated with PVC burden
reduction in athletes with ARVC. The novel risk prediction algorithm
does not seem to require any correction for its application to ARVC
athletes.
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Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is an inherited cardiomyopathy characterized by predominant
but not exclusive right ventricular (RV) myocardial fibrofatty
replacement.1–3 It usually is characterized by electrical and
morphologic RV alterations that are well known to be
associated with ARVC and an important increase in sudden
cardiac death (SCD) risk due to malignant ventricular
arrhythmias (VAs).1,3 Implantable cardioverter–
defibrillators (ICDs) are a viable option for dealing with
SCD risk in this patient population,4 but until recently, appro-
priate tools for adequate individual primary arrhythmic risk
stratification were scarce.5–8 Recently, a novel algorithm
for primary prevention ICD placement was developed
based on a large sample size international registry.9 Its perfor-
mance seems to be superior to that of the 2015 International
Task Force (ITF) consensus statement criteria, possibly lead-
ing to better patient-tailored therapy and increased net clin-
ical benefit.9
Several studies have assessed the correlation between
ARVC disease progression and malignant VA genesis with
engagement in sports.10–14 Physical exercise greatly
increases arrhythmic risk in such patients, and appropriate
detraining and sport practice reduction after disease
diagnosis reduce the long-term risk of VAs.15 No specific
adaptation of the current Cadrin-Tourigny et al algorithm
(https://arvcrisk.com) for individual levels of physical exer-
cise has been provided. Data for validation of this algorithm
in athletes are lacking, and transferability of the algorithm to
an external high-intensity athlete cohort with ARVC has yet
to be tested.
The aims of this study were to validate the Cadrin-
Tourigny et al algorithm and to report on disease progression
in a well-characterized, high-intensity athlete cohort of pa-
tients with ARVC.Methods
Patient population
All consecutive athletes with a definitive ARVC diagnosis
evaluated at the Arrhythmology and Sport Medicine Unit
of IRCCS Centro Cardiologico Monzino were enrolled in
the study. The analysis was approved by the local ethic re-
view board according to center’s legislation and complied
with the Declaration of Helsinki.Cohort definition
ARVC diagnoses were made by a dedicated heart team
composed of cardiac radiologists, electrophysiologists, and
cardiac pathologists, in accordance with the 2010 Revised
Task Force Criteria.16
A patient was classified as an athlete after a complete
sport cardiology evaluation according to the patient’s
training regimen: .6 hours per week of sports activity
with moderate-to-intense dynamic components (at least
6 METs); affiliation with an Italian or internationally
recognized sport federation; regular participation in sportcompetitions over the past year; or history of sport activity
without significant breaks/changes in training pattern/load
over the past 3 years.15,17 Endurance sports were defined
as those requiring sustained effort at .70% VO2max (eg,
cycling, swimming, rowing). Mixed sports were defined
as those requiring a mix of skill-based and aerobic/anaer-
obic exercise (eg, football, basketball, volleyball).18 All
patients regularly practiced their sport up until the time
of disease diagnosis or until their eligibility for participa-
tion in the sport was suspended immediately before
referral to our center.Patient in-hospital evaluation
After referral from the outpatient clinic to our centers or
during hospitalization after direct admission, all enrolled
athletes routinely underwent 12-lead baseline electrocar-
diography (ECG), 24-hour Holter ECG monitoring, com-
plete blood panel, stress ECG test, ARVC dedicated
cardiac ultrasound, and cardiac magnetic resonance
(CMR) analysis.
Baseline programmed electrical stimulation was per-
formed routinely as part of the arrhythmic risk assessment.
Three-dimensional endocavitary electroanatomic mapping
(EAM), percutaneous EAM-guided endomyocardial biopsy,
and genetic testing for diagnostic purposes were performed
based on indication and physician expertise. SCD risk strat-
ification analyses were performed in all patients per the ITF
consensus statement for ARVC treatment,4 and ICD place-
ment was performed accordingly.Evaluation of arrhythmic events and patient
follow-up
Upon disease diagnosis, 24-hour premature ventricular com-
plex (PVC) burden and all complex arrhythmic events
(PVCs, sustained ventricular tachycardia [SVT], ventricular
fibrillation/flutter [VF]) at baseline and noted in the patient
history were recorded, as was the reason for referral to our
center. At disease diagnosis, the patient’s sport eligibility sta-
tus was immediately suspended. Patients were instructed to
start a detraining period that highly reducing their training
regimen and to abstain from competitive sport practice per in-
ternational sport medicine guidelines.19,20
Patients underwent follow-up for disease progression
6 months after hospital discharge and then every 12 months
thereafter, or immediately after the occurrence of an
arrhythmic event and/or an emergency room visit. Holter
ECG was required at 6 months, with a surveillance proto-
col that required a minimum of one 24-hour Holter
recording every 24 months; however, monitoring proto-
cols were individualized based on physician expertise
and patient availability. For patients with an ICD, an
ICD interrogation was performed by dedicated personnel
every 6–8 months, and a summary check was performed
contextually at every follow-up visit. ECG stress test, car-
diac ultrasound, and CMR follow-up surveillance were not
mandated per protocol.
Table 1 Patient cohort baseline characteristics (N 5 25)
Demographics
Age at diagnosis (y) 36.1 6 14.0
Male 20 (80.0)
Training load (h) 7.4 6 1.3
Sport practice
Mixed sports 14 (56.0)
Volley 3 (12.0)
Football 7 (28.0)
Basket 4 (16.0)
Endurance sports 11 (44.0)
Cycling 5 (20.0)
Endurance running 4 (16.0)
Triathlon 1 (4.0)
Rowing 1 (4.0)
Reason for referral
Abnormalities at sport eligibility visit 18 (72)
ECG static abnormalities 5 (20.0)
PVCs 8 (32.0)
NSVT 5 (20.0)
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The primary outcome of the study was the first sustained VA
event after disease diagnosis. Sustained VAs were defined as
a composite of SCD, SVT, VF, or appropriate ICD interven-
tion for any of the previous arrhythmias.
For all patients who complied with the model require-
ments (as reported in the referred study and on the https://
arvcrisk.comWeb site),9 the expected VA rate was calculated
using the Cadrin-Tourigny et al predictive model. Yearly risk
was calculated at the time of disease diagnosis using the
values of the indicated variables as measured at disease diag-
nosis. Observed sustained VA rate at long-term follow-up
was calculated and compared to the algorithm-predicted
rate. Data on changes in 24-hour Holter ECG PVC number,
stress ECG result, and right ventricular ejection fraction
(RVEF) modification before and after the detraining protocol
also were collected and analyzed as secondary outcomes.Complex VAs during PA 5 (20)
SVT 3 (12.0)
VF with SCD 2 (8.0)
Unexplained loss of consciousness 2 (8)
Stress test ECG
Negative 6 (24.0)
PVCs suppressed by PA 10 (40.0)
PVCs unsuppressed by PA 5 (20.0)
NSVT 3 (12.0)
SVT 1 (4.0)
CMR imaging
RVEF (%) 47.5 6 8.1
LVEF (%) 56.3 6 5.2
Interventions
PES inducibility 9 (36.0)
SVT 7 (28.0)
VF 2 (8.0)
ICD placement 10 (40.0)
Subcutaneous ICD 4 (16.0)
Transvenous dual-chamber ICD 5 (20.0)
Transvenous single-chamber ICD 1 (4.0)
Values are given as mean 6 SD or n (%).Statistical analysis
All statistical analyses were performed using R Project for
statistical computing Version 3.5. Continuous variables are
expressed as mean 6 SD or median (interquartile range
[IQR]). Categorical variables are expressed as count (%).
Comparisons were performed using the independent sample
Student t test or the Mann-Whitney U test, as appropriate.
Kaplan–Meier analysis with log-rank test was used for statis-
tical inference of long-term outcome data. Predicted and
observed frequencies of sustained VAs were evaluated and
compared using a multivariate linear regression model. To
evaluate the effect of time over the total number of PVCs
and on RVEF, we fit a mixed model to the data in which
time was considered the fixed effect and the subject was
the random effect. The model ignores the missing data but
generates an output with the same observation number as
in the original dataset. The findings were considered statisti-
cally significant with a 2-tailed P ,.05.CMR 5 cardiac magnetic resonance; ECG 5 electrocardiography; ICD
5 implantable cardioverter–defibrillator; LVEF 5 left ventricular ejection
fraction; NSVT5 nonsustained ventricular tachycardia; PA5 physical activ-
ity; PES 5 programmed electrical stimulation; PVC 5 premature ventricular
complex; RVEF 5 right ventricular ejection fraction; SCD 5 sudden cardiac
death; SVT 5 sustained ventricular tachycardia; VA 5 ventricular
arrhythmia; VF 5 ventricular fibrillation.Results
Cohort overview
A total of 25 athletes with a definitive ARVC diagnosis were
enrolled in the study, with men representing the majority
(80%). Mean age at disease diagnosis was 36.16 14.0 years.
All patients were probands; 6 (24%) had a history of SCD in
their family at in-depth evaluation. Fourteen patients (56%)
practiced an aerobic/anaerobic mixed sport, and the remain-
ing 11 patients (44%) were endurance athletes.
The most common reason for referral was the presence of
abnormalities at a sport eligibility assessment (n 5 18
[72%]), followed by a symptomatic VA index event (n 5 5
[20%]), 2 of which required emergency resuscitation maneu-
vers on the field due to sudden cardiac arrest. At first evalu-
ation, the median number of PVCs on 24-hour Holter ECG
was 1000 (300–3500). Seven patients (28%) had a history
of documented nonsustained ventricular tachycardia, and
5 (20%) had documented sustained VAs. At CMR, mean
RVEF was 47.5% 6 8.1%, and mean left ventricular EFwas 56.3% 6 5.2%. Genetic testing analysis in 15 athletes
(60%) revealed 9 were positive for a pathogenic or likely
pathogenic mutation.
All patients underwent programmed electrical stimula-
tion. Nine patients (26%) had VAs induced in the electro-
physiology laboratory. EAM and EAM-guided
endomyocardial biopsy were performed in 10 patients
(40%). After disease diagnosis and appropriate arrhythmic
risk stratification, 10 ICD implantations (4 subcutaneous, 5
transvenous dual-chamber, 1 transvenous single-chamber)
(40.0%) were performed; an additional S-ICD placement
was deemed necessary but was refused by the patient. The
characteristics of the study population are given in Table 1.
Figure 1 Overall freedom from ventricular arrhythmias (VAs) in the overall cohort.
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Over median follow-up of 5.3 (3.2–6.6) years, a sustained
VA event was documented in 10 athletes (40.0%). Of these
episodes, 6 were recorded in patients with a previously im-
planted ICD. The cumulative freedom from VA events of
the cohort is shown in Figure 1 [overall 5-year freedom
from VA rate 0.84 (0.71–0.92)].
Within the cohort, 20 patients (80%) complied with the
Cadrin-Tourigny et al algorithm requirements, and their pre-
dicted risk was calculated. The clinical characteristics of this
subpopulation are given in Supplemental Table 1. Comparison
between predicted and observed VA rates over time are shown
in Figure 2. Events at follow-upwere well within the 95% con-
fidence interval of predicted rates, with a nonsignificant differ-
ence from the algorithm-predicted rate at any time during
follow-up [mean difference observed–predicted rate over
5 years –0.85% (–4.80% to 13.10%); P 5 .85]. The entire
risk data analysis is given in Supplemental Table 2.Disease progression during follow-up
After disease diagnosis and the beginning of the detraining
protocol, the characteristics of the athletes were collected
over time to monitor disease evolution. Over time, a
statistically significant 24 hour/PVC count reduction was
observed (P 5 .001) (mean reduction over first 18 months
–1682 6 573; P 5 .048; mean reduction from 18 months
to end of follow-up 160 6 680; P 5 .99) (Figure 3). A sub-
analysis revealed that the presence of beta-blocker did not
significantly influence the effect of clinical detraining on
the 24 hour/PVC count (P 5 .33) (Figure 4).Over a median of 8 (4–11) months, 21 patients (84%) un-
derwent a repeat stress ECG. A per patient qualitative
improvement in arrhythmic response at stress testing was
observed in 11 patients (52%), the same arrhythmic response
in 9 (43%), and a worsened arrhythmic stress ECG response
in only 1 (5%) (patient did not follow the detraining proto-
col). Graphic representation of stress ECG data over time is
shown in Figure 5. A total of 18 patients (72%) repeated
CMR examination after a median of 12 (9–13) months, and
RVEF had remained stable [CMR RVEF mean change
10.11% (–2.31% to 12.54%); P 5 .92; mean change
excluding 2 patients who did not follow the detraining proto-
col 11.43% (–0.23% to 13.11%); P 5 .09] (Figure 6).Discussion
ARVC is the first cause of sudden death among young indi-
viduals, and the risk has been reported as increased 5-fold in
active athletes,10,21 specifically in those training with a
high-intensity regimen and participating in endurance sport
competitions.3,10 Physical activity has been demonstrated
to increase disease progression and overall arrhythmic risk
in this patient population,11–14,22,23 with high-end strenuous
exercise and endurance training associated with the worst
outcomes.24 Given these findings, the current sport medicine
guidelines suggest complete abstention from competitive
sport training and a significant reduction even in leisure sport
activities by ARVC patients.19,20
Current scientific consensus indicates ICD placement in
high arrhythmic patients after arrhythmic risk assessment to
be the most effective treatment for ARVC patients.4
Figure 2 Comparison between observed and algorithm-predicted event rates. The algorithm-predicted risk showed almost perfect adherence to observed event
rates over follow-up. Time is considered from disease diagnosis.
Gasperetti et al Impact of Physical Activity on Risk Calculator for ARVC 5However, a high rate of ICDs implanted per VAs treated has
been reported in the ARVC literature, and due to device-
related economic burden and risks, a refinement of
arrhythmic stratification strategies was needed.9 In a recentFigure 3 Mean premature ventricular contraction (PVC)/24 hours over follow
observed at 6 months from detraining. Time is considered from disease diagnosis.study, Cadrin-Tourigny et al9 presented a novel arrhythmic
risk prediction model (https://arvcrisk.com) that proved
effective in an external experience.25 To date, no specific
correction for physical activity has been proposed.-up for the entire cohort. A clear reduction in PVC number can already be
Figure 4 Mean premature ventricular contraction (PVC)/24 hours over follow-up when stratifying for beta-blockers. Teal line indicates patients taking beta-
blocker. Red line indicates patients not taking beta-blocker. No significant difference in trend reduction between the 2 groups was observed. Time is considered
from disease diagnosis.
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ARVC cohort of highly characterized athletes undergoing
clinical detraining after disease diagnosis and to assess algo-
rithm transferability to an external cohort of high-intensity
athletes with ARVC. The enrolled cohort of athletes prac-
ticed physical activity almost up until disease diagnosis.
All practiced sports consisted of phases of high-end aerobicFigure 5 Changes in stress electrocardiogram (ECG) arrhythmic response overactivity, if not completely endurance sports. Patient popula-
tion characteristics and clinical results were comparable to
those of previously reported cohorts,15,26,27 except for
mean age, which was due to the small number of master ath-
letes (n 5 3) that positively skewed our data. The patients in
this cohort did not report major variations in training
regimen, and the overall training times over the years beforetime. PVC 5 premature ventricular complex; VT 5 ventricular tachycardia.
Figure 6 Changes in cardiac magnetic resonance right ventricular ejection
fraction (CMR RVEF) over time.
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tion of the sports history of these patients.
Primary arrhythmic risk evaluation in athletes
In this cohort, the Cadrin-Tourigny et al algorithm proved
reliable in predicting arrhythmic events at all analyzed
follow-up points. All patients used for the transferability
analysis complied completely with the applicability criteria
of the algorithm and were diagnosed with classic ARVC.
No gross discrepancies between the a priori and the observed
arrhythmic risk were identified in our evaluation. The
currently codified clinical parameters seem to account for
the increased arrhythmic risk to which athletes are exposed.
The impact of exercise on athletes may already be evidenced
as lower RVEF and higher PVC counts over 24 hours, lead-
ing to higher algorithm-predicted arrhythmic risk.
Of note, our cohort underwent mandatory detraining.
Therefore, a potential objection to these results could be
that if sport-induced RV remodeling in ARVC patients
were fully reversible, at long-term follow-up (eg, at 5 years)
this cohort might be more similar to a nonathlete ARVC
cohort than to an active athlete (but not yet diagnosed)
ARVC cohort from an arrhythmic point of view.
Currently, no proof of complete reversibility of sport-
induced remodeling in ARVC patients has been presented.
High-end endurance training is associated with worse
long-term clinical outcomes, but the mechanisms behind
this association are not completely understood nor has
the long-term impact of clinical detraining been as-
sessed.15 Long-term assessments of ARVC patients who
have been practicing endurance sports and who underwent
mandatory detraining are limited by both sample size and
length of follow-up, so we believe this assessment in a
specific ARVC subpopulation to be important for primary
risk stratification and for better understanding of the dis-
ease. However, even if sport-induced remodeling were to
be completely reversible, some time still would be
required after implementation of the detraining protocol
for it to take effect. In our cohort, the perfect patternmatching between the a priori algorithm-predicted and
observed arrhythmic risk was assessed across the entire
duration of follow-up, even during the early years when
a theoretically regressing but not yet regressed remodeling
should be present as an additional factor unaccounted by
the algorithm. Larger case series and multicenter studies
are needed to further assess the impact and role of both
endurance training and clinical detraining in ARVC pa-
tients, as well as to completely validate the algorithm in
a sportsmen setting. However, data from this first report
seem to favor implementation of the algorithm even in
this subset of patients.Impact of clinical detraining on patient
characteristics
Clinical detraining in ARVC athlete patients was associated
with a clear reduction in the 24 hour/PVC burden over
time. A quantifiable PVC reduction trend is shown in
Figure 3. Patients with a higher PVC count generally were
also started on beta-blocker therapy, but as shown in
Figure 4, both detraining and detraining1beta-blocker man-
agement strategy led to similar percentage reductions in PVC
burden. Of note, the decrease in PVC burden seems to be
maximal within the first 6 months after the detraining inter-
val, plateaus at around 18 months of complete detraining,
and remains stable for the duration of follow-up. However,
no correlation between the reduction in PVC burden and
long-term outcomes has been performed due to the number
of patients and trial structure. We agree with Wang et al15
in affirming that clinical detraining is not a strategy aimed
at altering ICD placement decision-making but should repre-
sent a therapeutic add-on, as also suggested by current inter-
national guidelines.
Upon clinical detraining, more than half of the patients
who repeated stress ECG reported improvement in
arrhythmic findings during follow-up (Figure 5), potentially
indicating a role of exercise in progressively self-elicited, ex-
ercise-associated arrhythmias.
Although clinical detraining clearly reduced PVC burden
and improved arrhythmic stress response, it did not improve
RVEF. At 1-year follow-up, in most patients RVEF remained
stable, with both clinically and statistically nonsignificant
changes. Cessation of physical activity seemed to lead to sta-
bilization of disease progression but not to disease reversal.
This result does not seem to contrast the data in a recent study
from Chivulescu et al,28 who reported progressive deteriora-
tion of both morphologic and functional characteristics at
CMR of ARVC patients over long-term (median 7.0 years)
follow-up. Cessation of physical exercise, the main disease
progression factor in our cohort, probably slowed, but did
not stop, disease progression. Additional worsening probably
would have been detected if morphologic assessment had
been performed later (eg, at 5 years). To better assess the
impact of clinical detraining on RV contractility, further
assessments with large sample sizes and longer follow-up pe-
riods are required. Of note, studying the effect of detraining
8 Heart Rhythm, Vol-, No-,- 2020on ventricular reverse remodeling in ARVC subpopulations
with a genotype more prone to heart failure (eg,
desmoglein-2 [DSG-2]) would be of great interest for
advancing the entire field.Outliers not following clinical detraining
Two patients were classified as outliers because of their
refusal to comply with clinical detraining. The first patient
met the clinical criteria for ICD implantation in primary pre-
vention but refused to undergo the procedure. The patient
kept training regularly and presented at the subsequent
follow-up visit with increased PVC burden, several runs
of nonsustained ventricular tachycardia on Holter ECG
analysis, decreased RVEF, and report of several syncopal
events during physical activity. ICD implantation was again
proposed, and the patient agreed. Clinical detraining was
recommended, and this time the patient complied. Twelve
months later, PVC burden was reduced, and RVEF had re-
mained stable.
The second patient, who had been implanted with an
S-ICD for primary prevention, refused to comply with
clinical detraining for 20 months. The patient continued
practicing high-end endurance sports (half-marathon and
cycling). After significant deterioration of all clinical pa-
rameters had been assessed and after a multidisciplinary
consultation that included family members, the patient un-
derstood the importance of clinical detraining and agreed
to comply. The patient’s clinical status remained stable
thereafter.Study limitations
This study represents the first analysis of a novel ARVC
calculator for risk of primary VAs in a cohort of ARVC
patients with an extensive athletic background. Study limita-
tions are mostly due to the retrospective nature of the study
and the patient follow-up protocol that, although fairly stan-
dardized, was not prespecified, possibly introducing some
variability to the presented results. The single-center nature
of the study may contribute to referral bias, as the entire
cohort was extracted from a third-level referral center. In
addition, no stratification between gene-positive and gene-
elusive patients was performed due to the small sample
size. Further studies with prospective evaluation and larger
sample sizes are needed to completely confirm these results.Conclusion
This first analysis of an external cohort seems to validate the
use of the Cadrin-Tourigny et al algorithm in athletes. The
algorithm seems to account for the practice of high-end
endurance sports and does not require specific adjustments.
Mandatory clinical detraining has a positive effect on the
24 hour/PVC burden and occurrence of dysrhythmia on
stress ECG at mid-term follow-up, with no significant reverse
remodeling of RVEF observed. Additional multicenter
studies with larger sample sizes are required to confirm the
results obtained.Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at https://doi.org/10.1016/j.hrthm.2020.
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